Merck & Co (MRK) | Stock Overview & Key Data
Merck & Co Performance Comparison
Stock Range
Today's Range
Low: $82.80
High: $85.18
on September 12, 2025
52 Week Range
Low: $73.31
High: $119.38
on May 15, 2025
on September 18, 2024
All-Time High: $134.63 on June 24, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$206.8B
EPS
6.49
P/E Ratio (TTM)
12.76
Forward P/E
8.81
P/B Ratio
4.23
PEG Ratio
-0.72
Div. Yield
3.01%
ROE
35.42%
Beta
0.379
Debt to Equity
72.16
Financial Highlights
Profitability
Gross Margin
77.50%
Operating Margin
37.47%
Profit Margin
25.79%
Returns and Earnings
Return on Assets (TTM)
13.01%
Return on Equity (TTM)
35.42%
EBITDA
$26.0B
Net Income (TTM)
$16.4B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$25.17
Quarterly Revenue Growth (YoY)
-1.90%
Quarterly Earnings Growth (YoY)
-18.80%
Dividend Information
Last 12-Month Dividend
$2.39
Current Dividend Yield
3.01%
3-Year Average Dividend Yield
0.71%
3-Year Average Annual Dividend
$2.77
3-Year Total Dividends
$8.31
Ex-Dividend Date
March 17, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Merck & Co MRK | 206.84B Mega-cap | -2.24% | 3.13% | 1.21% | -11.29% | -16.50% | -28.53% | -5.60% | 1.14% |
| Eli Lilly and LLY | 691.79B Mega-cap | 3.88% | 18.13% | -6.98% | -8.09% | -2.91% | -18.22% | 144.55% | 389.97% |
| Johnson & Johnson JNJ | 428.83B Mega-cap | -0.21% | 3.06% | 13.66% | 9.34% | 23.64% | 7.58% | 6.24% | 19.36% |
| AbbVie ABBV | 385.71B Mega-cap | 2.72% | 9.92% | 13.47% | 2.96% | 21.68% | 12.41% | 51.55% | 142.28% |
| Amgen AMGN | 148.80B Large-cap | -2.56% | -3.01% | -7.03% | -11.56% | 6.60% | -16.83% | 19.62% | 11.61% |
| Gilead Sciences GILD | 142.13B Large-cap | -0.43% | -4.56% | 2.23% | 0.49% | 24.67% | 38.33% | 74.62% | 76.10% |
Ownership & Short Interest
Insider Ownership
0.07%
Institutional Ownership
80.59%
Shares Short
24M
Short Ratio
1.96
Short % of Shares Outstanding
1.06%
Average 10-Day Volume
12M
Average 90-Day Volume
11M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is MRK's 52-week high and low?
- In the last 52 weeks, Merck & Co reached a high of $119.38 (on September 18, 2024) and a low of $73.31 (on May 15, 2025).
- What is the market cap and P/E ratio for MRK?
- Curious about Merck & Co's size and valuation? Its market capitalization stands at 206.84B. When it comes to valuation, the P/E ratio (trailing twelve months) is 12.76, and the forward P/E (looking ahead) is 8.81.
- Does MRK pay dividends? If so, what's the yield?
- Yes, Merck & Co is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 3.01%, and the company has paid an average of $2.77 per share annually over the past 3 years.
- Who are Merck & Co's main competitors or similar companies to consider before investing?
When looking at Merck & Co, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY691.79B Healthcare Drug Manufacturers - General -18.22% 144.55% Johnson & Johnson
JNJ428.83B Healthcare Drug Manufacturers - General 7.58% 6.24% AbbVie
ABBV385.71B Healthcare Drug Manufacturers - General 12.41% 51.55% Amgen
AMGN148.80B Healthcare Drug Manufacturers - General -16.83% 19.62% Gilead Sciences
GILD142.13B Healthcare Drug Manufacturers - General 38.33% 74.62% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Merck & Co., Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Merck & Co's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 35.42%, the Debt to Equity ratio from the most recent quarter is 72.16, and its Gross Profit Margin stands at 77.50%.
- What is the recent revenue and earnings growth for MRK?
- Looking at Merck & Co's growth, its revenue over the trailing twelve months (TTM) was $64B. Compared to the same quarter last year (YoY), quarterly revenue grew by -1.90%, and quarterly earnings saw a YoY growth of -18.80%.
- How much of MRK stock is held by insiders and institutions?
- Wondering who owns Merck & Co stock? Company insiders (like executives and directors) hold about 0.07% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 80.59%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.